FDA Clearance Tracker · P140031-S087
SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Heart Valves
Last checked: Nov 20, 2026Latest source record: Jul 29, 2019 (this decision)Source: openFDAMethods & limitations
Decided
Jul 29, 2019
Approved
Time to decision
73 days
Received May 17, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P140031-S087
- Device name
- SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Heart Valves
- Applicant
- Edwards Lifesciences, LLC
- Applicant location
- Irvine, CA
- Received
- May 17, 2019
- Decided
- Jul 29, 2019
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P140031
Device type
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for updates to the labeling of the SAPIEN 3 Transcatheter Heart Valve and Accessories and SAPIEN 3 Ultra Transcatheter Heart Valve and Accessories regarding additional valve-in-valve sizing guidance for implantation inside the Edwards INSPIRIS RESILIA aortic valve model 11500A.
Source documents
Other decisions for Edwards Lifesciences, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- PASCAL Precision Transcatheter Valve Repair SystemPMA supplement
P220003-S029 · Decided Oct 20, 2026 · 180 days after receipt · Panel Track
Device type: Tricuspid valve repair device, percutaneously delivered (NPS) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.